Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Other
- Reported indication
- Peripheral vasodilator formerly approved for peripheral arterial occlusive disease (now withdrawn)
- First approval
- Not recorded
- Development stage
- Withdrawn/suspended for neuro-cardiac safety
- ChEMBL max phase
- 4 / 4 (development scale, not regulatory approval)
- Synonyms
- Buflomedil
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatOtherMalen = Seven groups of rats, group sizes not statedIntravenous (tail vein) or topical in the rewarming bath10 mg/kg by tail vein injection, or 24 mg buflomedil in the…Before cooling, immediately after cooling, or during rewarming
Model: Acute experimental freeze injury of the left hindpaw cooled to footpad temperature of -15 degrees C followed by rapid rewarming at 40 degrees C
There was no significant difference in mean cast weights between frozen hindpaws across the seven groups, although buflomedil increased mean cast weight of control hindpaws in two groups. Buflomedil did not improve vascular patency in this acute frostbite model.
Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.